first
vaccin
result
empir
studi
mainli
compos
whole
organ
live
attenu
kill
inactiv
toxin
major
vaccin
studi
develop
later
also
use
convent
approach
select
appropri
antigen
antigen
select
key
step
vaccin
develop
pregenom
era
timeconsum
mani
limit
properti
aim
molecul
access
immun
system
induc
protect
immun
conserv
within
speci
contain
region
high
variabl
select
good
candid
vaccin
antigen
primarili
base
capac
induct
protect
antibodi
probabl
explain
effect
vaccin
current
avail
mainli
induc
protect
humor
immun
respons
recent
molecular
biolog
method
appli
develop
new
vaccin
primarili
enabl
largescal
product
subunit
peptidebas
vaccin
antigen
nevertheless
small
number
avail
vaccin
base
recombin
antigen
strategi
convent
vaccinolog
pose
limit
develop
effect
vaccin
varieti
infecti
diseas
develop
vaccin
pathogen
show
import
antigen
variat
cultiv
laboratori
remain
great
challeng
current
new
approach
use
highthroughput
technolog
use
identif
new
vaccin
candid
molecul
public
haemophilu
influenza
genom
first
pathogen
complet
genom
sequenc
publish
result
approach
genom
analysi
use
new
technolog
highthroughput
sequenc
open
mind
scientist
rang
new
possibl
approach
studi
microorgan
mark
begin
new
era
vaccin
develop
identif
pathogen
candid
antigen
base
knowledg
genom
pathogen
understand
microbi
biolog
hostpathogen
interact
approach
call
revers
vaccinolog
approach
favor
recent
year
use
highthroughput
technolog
field
genom
proteom
immunom
among
omic
expand
enorm
number
avail
viral
parasit
genom
sequenc
grow
continu
import
advanc
made
make
new
biostatist
bioinformat
tool
avail
candid
gene
prospect
current
genom
era
mark
major
impact
abil
find
new
candid
vaccin
antigen
develop
effect
vaccin
one
approach
may
use
analyz
dna
data
sequenc
order
identifi
vaccin
candid
molecul
silico
analysi
complet
genom
requir
cultiv
pathogen
use
varieti
comput
resourc
process
dna
sequenc
data
avail
inform
protein
function
cell
transport
local
antigen
process
immunogen
comput
analysi
may
enabl
identif
dna
sequenc
encod
protein
relev
featur
potenti
vaccin
target
impact
silico
analysi
vaccin
develop
exemplifi
first
studi
publish
use
approach
capsular
polysaccharidebas
vaccin
neisseria
meningitidi
serogroup
c
avail
serogroup
b
structur
ident
polysial
acid
structur
present
human
cell
entir
genom
sequenc
virul
n
meningitidi
serogroup
b
strain
account
major
meningococc
diseas
burden
unit
state
europ
analyz
identifi
candid
new
vaccin
bacteri
genom
screen
use
bioinformat
tool
identifi
rel
conserv
surfaceexpos
outer
membran
protein
antigen
open
read
frame
orf
thu
select
immunoproteom
method
use
select
immunogen
meningococc
antigen
would
elicit
protect
immun
five
genomederiv
candid
antigen
compon
ration
design
vaccin
n
meningitidi
serogroup
b
formul
four
antigen
novarti
switzerland
induc
high
titer
bactericid
antibodi
phase
iii
clinic
trial
multival
vaccin
formul
propos
overcom
issu
antigen
divers
strain
n
meningitidi
would
expect
stimul
immun
respons
capabl
recogn
multipl
antigen
variant
promis
result
new
vaccin
candid
may
critic
proof
concept
stage
novel
approach
significantli
shift
paradigm
vaccin
develop
microbiolog
sequencebas
approach
genomewid
screen
use
function
select
method
dna
microarray
gene
knockout
librari
screen
cdna
express
librari
use
patient
sera
employ
prospect
vaccin
candid
review
ref
approach
allow
evalu
possibl
immunogen
immunoprotect
role
molecul
either
surfac
express
secret
pathogen
therebi
enabl
identif
candid
antigen
identifi
methodolog
appli
convent
vaccinolog
mean
even
molecul
express
low
level
certain
condit
test
potenti
candid
vaccin
brief
genom
coupl
new
omic
field
studi
transcriptom
proteom
immunom
enabl
identif
vaccin
candid
molecul
base
pathogen
genom
analysi
highthroughput
sequenc
technolog
also
use
understand
molecular
biolog
sever
virus
parasit
recent
genomicbas
approach
allow
identif
potenti
novel
viral
parasit
target
includ
vaccin
infecti
diseas
sever
acut
respiratori
syndrom
sar
aid
trypanosomiasi
malaria
pathogen
develop
multipl
strategi
evad
immun
respons
one
commonli
use
antigen
variat
immun
respons
target
genet
variabl
observ
microorgan
especi
pathogen
account
capac
microbi
pathogen
adapt
genet
distinct
host
differ
antibiot
immun
system
defens
mechan
high
intraspeci
variabl
import
limit
factor
develop
vaccin
sever
diseas
hiv
hepat
c
viru
hcv
plasmodium
meningococcu
genotyp
differ
among
infect
mycobacterium
tuberculosi
strain
also
point
potenti
factor
influenc
efficaci
bacillu
bcg
vaccin
tuberculosi
vaccin
extens
use
studi
show
wide
variat
efficaci
among
popul
geograph
region
worldwid
entir
microorgan
genom
sequenc
obtain
rel
inexpens
quickli
fact
make
feasibl
whole
genom
data
avail
multipl
isol
singl
pathogen
technolog
advanc
provid
basi
excit
newli
propos
concept
pangenom
accord
concept
bacteri
speci
could
character
global
gene
repertoir
contain
gene
share
strain
core
genom
gene
share
strain
dispens
genom
addit
genet
variant
gene
found
strain
character
dna
sequenc
analysi
concept
use
character
intraspeci
divers
novel
approach
discoveri
new
vaccin
candid
molecul
pangenom
revers
vaccinolog
thu
develop
effect
multival
broad
coverag
genomebas
vaccin
probabl
result
approach
includ
genom
multipl
isol
microbi
pathogen
yet
underrepres
strain
target
multival
vaccin
may
becom
matter
concern
broad
vaccin
coverag
establish
serotyp
replac
phenomenon
minor
bacteri
serotyp
becom
predomin
time
document
introduct
heptaval
antipneumococc
conjug
vaccin
attribut
fact
strain
target
vaccin
abl
escap
vaccin
select
pressur
ongo
effort
data
mine
inform
pathogen
genom
alreadi
made
avail
effect
help
identifi
new
potenti
vaccin
target
infecti
diseas
figur
howev
new
approach
use
power
technolog
genom
pangenom
revers
vaccinolog
function
structur
genom
advantag
limit
consid
ration
design
vaccin
develop
project
gener
methodolog
use
identif
analysi
vaccin
candid
antigen
base
assumpt
surfac
secret
protein
induc
protect
humor
immun
respons
true
almost
extracellular
pathogen
presenc
antibodi
alway
associ
protect
intracellular
pathogen
elicit
antibodi
tcell
immun
respons
import
properti
candid
antigen
evalu
fact
despit
amount
avail
data
genom
pathogen
human
genom
gene
molecul
mechan
involv
pathogen
virul
host
defens
still
clear
understand
mechan
microbi
infect
immun
respons
remain
major
challeng
vaccin
develop
could
explain
rel
slow
progress
made
develop
new
effici
vaccin
spite
emerg
highthroughput
sequenc
technolog
advanc
bioinformat
much
research
still
need
novel
vaccin
develop
contribut
microbi
gene
express
diseas
activ
protect
immun
respons
understood
current
data
show
wide
varieti
new
molecul
potenti
constitut
new
vaccin
target
choic
select
method
new
vaccin
antigen
therebi
critic
step
depend
accumul
knowledg
field
bioinformat
genom
immunolog
patholog
microbiolog
parasitolog
virolog
hostpathogen
interact
also
influenc
host
background
thu
differ
anim
model
human
popul
age
specif
nutrient
defici
coinfectioncomorbid
among
host
condit
influenc
immun
respons
given
pathogen
vaccin
accumul
evid
genet
control
infecti
diseas
rare
primari
immunodefici
shown
caus
suscept
either
multipl
infecti
agent
singl
type
infecti
agent
rare
mendelian
inherit
twin
studi
provid
evid
genet
control
complex
segreg
analys
explicitli
model
effect
gene
environ
reveal
either
multigen
predisposit
genet
predisposit
base
major
gene
big
influenc
phenotyp
relat
diseas
sever
candid
gene
associ
infecti
diseas
candid
gene
approach
support
role
human
genet
resist
suscept
infecti
diseas
recent
rna
interfer
use
exploit
human
cell
model
infect
variou
agent
elucid
pathogen
virul
mechan
capabl
subvert
host
pathway
involv
immun
regul
pathogen
kill
respons
approach
use
discov
associ
differ
preferenti
immunoregulatori
network
involv
hostpathogen
interact
suscept
versu
resist
host
approach
howev
restrict
wellknown
gene
sever
genomewid
linkag
analys
perform
map
new
resist
suscept
gene
major
gene
map
chromosom
schistosomiasi
chromosom
tuberculosi
chromosom
leprosi
chromosom
viscer
leishmaniasi
blood
infect
load
plasmodium
falciparum
mild
malaria
genet
link
chromosom
identif
gene
underli
complex
diseas
remain
challeng
task
gene
identifi
nevertheless
chromosom
tnf
chromosom
pacrg
chromosom
polymorph
associ
schistosomiasi
mild
malaria
leprosi
respect
first
genomewid
associ
studi
infecti
diseas
publish
fellay
et
al
found
associ
hlab
hlac
hiv
viru
load
diseas
progress
recent
sever
genomewid
associ
studi
publish
malaria
hepat
b
hepat
c
best
signal
associ
found
hbb
locu
sever
malaria
hladp
locu
hepat
b
locu
hepat
c
studi
base
singl
nucleotid
polymorph
snp
array
snp
genotyp
hiv
malaria
hepat
b
studi
snp
analyz
hepat
c
studi
twin
studi
recent
establish
genet
variat
influenc
respons
hepat
b
diphtheria
tetanu
measl
mump
rubella
polio
h
influenza
type
b
pertussi
bcg
vaccin
studi
led
estim
herit
defin
ratio
genet
varianc
total
varianc
immun
respons
earli
paper
report
herit
antibodi
respons
hepat
b
surfac
antigen
vaccin
adult
young
children
respect
stress
high
level
antibodi
hepat
b
surfac
antigen
correl
protect
infect
persist
carriag
herit
vaccin
respons
gener
high
reach
antibodi
respons
measl
vaccin
stress
immun
mechan
respons
protect
larg
unknown
varieti
infecti
diseas
also
immunolog
correl
protect
need
monitor
efficaci
vaccin
studi
genet
protect
respons
vaccin
influenc
genet
background
support
twinbas
populationbas
associ
studi
reveal
associ
hla
nonhla
candid
gene
respons
hepat
b
influenza
measl
rubella
bcg
vaccin
howev
candid
simultan
test
research
group
except
studi
hennig
et
al
analyz
candid
gene
like
gene
involv
resist
particular
infecti
diseas
respons
correspond
candid
vaccin
therefor
gene
associ
resist
suscept
infect
diseas
consid
candid
potenti
involv
respons
vaccin
gene
identifi
genomewid
approach
infecti
diseas
particular
interest
convers
gene
affect
respons
vaccin
may
analyz
potenti
role
resist
suscept
correspond
diseas
may
time
move
candid
gene
approach
genomewid
linkag
andor
associ
approach
order
identifi
gene
control
respons
vaccin
figur
like
popul
differ
genet
background
differ
genet
control
infecti
diseas
particular
infecti
diseas
involv
loci
may
evidenc
popul
live
africa
may
detect
anoth
one
live
asia
ethnic
group
live
area
also
differ
abil
control
infect
diseas
exampl
fulani
whose
genet
background
clearli
differ
ethnic
group
west
africa
compar
sympatr
ethnic
group
sever
phenotyp
relat
malaria
resist
fulani
produc
higher
antibodi
level
mossi
rimaib
lower
parasit
densiti
fewer
milder
malaria
attack
indic
fulani
resist
malaria
mossi
rimaib
similarli
known
popul
differ
respons
vaccin
suggest
popul
differ
frequenc
protect
allel
poland
et
al
report
nativ
innu
inuit
caucasian
schoolchildren
differ
product
antibodi
measl
antigen
vaccin
canada
addit
malawi
uk
popul
strikingli
differ
level
protect
follow
bcg
vaccin
ie
malawi
uk
product
respons
mycobacterium
antigen
furthermor
nativ
children
navajo
white
mountain
apach
alaska
children
gener
us
popul
differ
incid
diseas
due
h
influenza
type
b
vaccin
indic
nativ
children
suscept
children
us
respons
vaccin
also
weaker
understand
genet
basi
variat
vaccin
respons
may
lead
investig
consid
differ
vaccin
strategi
group
differ
genet
background
combin
high
throughput
methodolog
multifactori
analys
may
help
identif
genet
marker
affect
immun
physiolog
respons
lead
seriou
advers
effect
thu
allow
identif
group
risk
vaccineinduc
advers
event
would
entitl
prevent
therapi
altern
vaccin
formul
way
exposur
infecti
agent
current
immun
statu
eg
immunocompromis
subject
gender
age
could
taken
account
minim
rate
vaccin
failur
vaccin
advers
event
targetedgroup
vaccin
approach
requir
inform
human
group
interest
effort
particularli
need
studi
variou
popul
africa
genet
divers
import
world
data
lack
popul
intern
scientif
medic
commun
would
abl
screen
million
polymorph
within
potenti
target
group
also
suggest
profil
base
individu
inform
genet
inform
age
gender
would
allow
predict
need
receiv
given
vaccin
ie
suscept
infect
number
amount
dose
need
likelihood
respons
likelihood
advers
event
therebi
make
possibl
develop
person
vaccin
approach
stage
develop
health
system
individu
would
genotyp
genom
scale
would
becom
polit
econom
choic
come
era
person
vaccin
howev
develop
method
eventu
allow
us
predict
individu
respons
vaccin
basi
individu
inform
includ
genomewid
genotyp
challeng
less
technolog
conceptu
emerg
new
technolog
microarray
technolog
recent
next
gener
sequenc
technolog
give
illus
gene
control
complex
phenotyp
would
easili
identifi
due
fact
obtain
huge
amount
biolog
data
one
sampl
exampl
wholegenom
transcriptom
analyz
use
one
array
individu
snp
simultan
genotyp
use
snp
array
individu
last
gener
affymetrix
chip
allow
analysi
million
snp
nextgener
sequenc
solexaillumina
solidabi
allow
analysi
transcriptom
small
rna
dna
methyl
snp
copi
number
variat
genom
scale
technolog
produc
huge
amount
data
need
store
transfer
care
analyz
interpret
statist
analysi
signific
challeng
number
statist
test
perform
tackl
multitest
problem
new
approach
propos
approach
use
genomewid
studi
provid
signific
result
statist
point
view
howev
clear
biolog
inform
miss
lack
highlight
result
obtain
genomewid
linkag
associ
infecti
diseas
instanc
fellay
et
al
estim
polymorph
identifi
explain
viru
load
varianc
studi
popul
suggest
effect
gene
detect
strikingli
genomewid
associ
studi
detect
associ
protect
sever
malaria
hemoglobin
correct
multitest
sever
gene
genet
variant
associ
sever
malaria
independ
popul
clear
biolog
interpret
data
need
integr
variou
biolog
data
store
differ
databas
statist
approach
make
use
data
central
concept
drive
develop
new
approach
molecular
network
figur
repres
concept
context
infecti
diseas
concept
stimul
develop
gene
priorit
tool
propos
candid
gene
lie
within
chromosom
region
link
diseas
approach
use
impli
gene
involv
diseas
share
function
properti
andor
map
gene
protein
network
frequent
approach
rank
candid
basi
similar
set
train
gene
demonstr
involv
diseas
review
ref
biolog
concept
gene
network
impli
exist
genegen
interact
gener
taken
account
genomewid
linkag
associ
analys
genegen
interact
explicitli
includ
model
use
linkag
associ
analys
statist
approach
propos
detect
interact
also
studi
vaccin
respons
furthermor
influenc
tirap
polymorph
clinic
diseas
caus
tuberculosi
found
depend
pathogen
genotyp
suggest
exist
bacteri
genehuman
gene
interact
obvious
genegen
interact
studi
genom
scale
pose
addit
multitest
problem
must
tackl
addit
approach
gener
limit
low
order
interact
effort
need
develop
statist
approach
make
use
whole
biolog
network
analysi
genet
variat
gene
express
level
could
also
provid
help
understand
polymorph
could
perturb
transcript
network
infecti
diseas
microarray
studi
base
mice
infect
either
virul
nonvirul
pathogen
identifi
gene
express
pattern
associ
infecti
diseas
indic
exist
least
one
transcript
network
perturb
virul
strain
moreov
gene
express
profil
shown
discrimin
genet
cerebr
malariaresist
versu
genet
cerebr
malariasuscept
mice
earli
late
stage
infect
p
berghei
anka
indic
genet
variant
direct
least
one
transcript
network
toward
state
conduct
cerebr
malaria
death
suscept
mice
infect
human
blood
cell
gene
express
profil
associ
clinic
statu
patient
infect
differ
pathogen
use
monitor
respons
bcg
vaccin
children
although
genom
studi
perform
field
vaccin
anticip
biolog
network
concept
would
use
way
poland
et
al
propos
immunerespons
network
theori
wherebi
respons
vaccin
view
cumul
result
gene
interact
find
natur
infect
individu
mous
model
infecti
diseas
support
hypothesi
urg
effort
perform
genomewid
studi
vaccin
mice
human
compar
result
obtain
natur
infect
author
suggest
network
combin
individu
genom
profil
may
lead
predict
respons
vaccin
big
challeng
requir
biolog
network
captur
relev
inform
includ
effect
genet
biolog
inform
age
gender
etc
impli
one
would
abl
predict
effect
singl
combin
perturb
polymorph
molecular
phenotyp
figur
purpos
regulatori
network
model
method
would
use
model
construct
avail
data
predict
molecular
cellular
phenotyp
provid
work
hypothes
test
lead
improv
initi
model
interestingli
immun
respons
systemlevel
tool
made
avail
thu
system
biolog
new
ration
approach
give
comprehens
understand
network
interact
compon
immun
respons
pathogen
antigen
concept
recent
review
appli
identifi
signatur
protect
would
evalu
design
new
vaccin
predict
vaccin
efficaci
system
vaccinom
emerg
research
strategi
vaccin
develop
alreadi
appli
identifi
signatur
protect
influenza
yellow
fever
vaccin
nevertheless
current
tool
manag
small
biolog
network
challeng
develop
new
approach
allow
model
larg
regulatori
network
conclus
genom
infecti
agent
acceler
identif
new
relev
vaccin
candid
antigen
includ
antigen
conserv
strain
collect
cover
divers
strain
target
protect
immun
respons
genomebas
approach
help
develop
vaccin
old
far
uncontrol
infecti
diseas
expect
develop
countri
may
play
critic
role
design
vaccin
emerg
infecti
diseas
well
noninfecti
diseas
identif
relev
molecular
target
requir
research
protect
immun
respons
develop
immunolog
tool
recent
investig
systemat
search
viral
proteinhuman
protein
interact
open
new
avenu
understand
hostpathogen
interact
therapeut
strategi
research
mechan
action
adjuv
use
restraint
relev
anim
model
mandatori
human
genet
variat
also
taken
account
analyz
respons
vaccin
vaccin
strategi
may
adapt
target
group
order
optim
vaccin
efficaci
reduc
risk
advers
event
similarli
possibl
person
vaccin
strategi
appropri
dose
schedul
even
molecular
compon
vaccin
suggest
would
base
individu
inform
includ
genomewid
genet
inform
impli
abil
predict
individu
respons
vaccin
challeng
develop
new
tool
necessari
accur
construct
model
molecular
network
perturb
caus
either
absenc
respons
advers
event
